Techorizon Launches Latest Version of THeCRF 4.0
Techorizon has announced the launch of the latest version of its electronic data capture tool, THeCRF 4.0 .
“Techorizon has remodeled its data collection folder with new solutions that allow you to leave the hospital perimeter and enter patients' homes more easily via smartphone, tablet or PC. The integration of external tools such as wearable devices are no longer an option but are in fact becoming an alternative to future diagnostic models,” commented Silvio Severini, Managing Director of Techorizon.
The capabilities of THeCRF include:
- Welcome Dashboard with a customizable widget
- The automatized set up
- Third party integration module
- Cohort Management and Multiple Case Report Form (CRF) implementation tool
- On-demand reporting schedules
- Data export in the most popular formats
- Post-it comment and note functionality
- Image Management and evaluation
- Integrated digital signing
For more information, click here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
